Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Biogen, Inc. (NasdaqNM:BGEN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
14 Cambridge Center
Cambridge, MA 02142
Phone: (617) 679-2000
Fax: (617) 679-2617
Email: corpcomm@biogen.com
Employees (last reported count): 1,475
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 500
 ·Nasdaq 100
Ownership
·Insider and 5%+ Owners: 4%
·Over the last 6 months:
 · 6 insider sells; 282.0K shares
  (4.5% of insider shares)
·Institutional: 59% (61% of float)
(935 institutions)
·Net Inst. Buying: 1.11M shares (+1.26%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Biogen, Inc. is a biopharmaceutical company principally engaged in the business of developing, manufacturing and marketing drugs for human healthcare. Biogen currently derives revenues from sales of its Avonex (Interferon beta-1a) product for the treatment of relapsing forms of multiple sclerosis, and from royalties on worldwide sales by the Company's licensees of a number of products covered under patents controlled by the Company. Such products include certain forms of alpha interferon, hepatitis B vaccines and hepatitis B diagnostic test kits, among others. Biogen continues to have an active development program related to Avonex, and is conducting several important clinical trials of the product. Biogen also continues to devote significant resources to its other ongoing development efforts.
More from Market Guide: Expanded Business Description

Financial Summary
BGEN is a biopharmaceutical company primarily engaged in the business of developing, manufacturing and marketing drugs for human health care. BGEN currently derives revenues from sales of AVONEX and from royalties on worldwide sales by licensees. For the six months ended 6/01, total revenues rose 11% to $497.7 million. Net income decreased 26% to $144 million. Results reflect an increase in the sales volume of AVONEX, offset by decreased gains on securities.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

James Vincent, 61
Chairman
$1.5M$36.2M
James Mullen, 42
Pres, CEO, Chief Operating Officer, Director
1.0M7.7M
David Buckley
Exec. VP, Technical Operations
--  --  
Sylvie Gregoire
Exec. VP, Technical Operations
--  --  
Hans-Peter Hasler
Exec. VP, Commercial Operations
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:BGENAs of 31-Aug-2001
Price and Volume
52-Week Low
on 11-Oct-2000
$47.125
Recent Price$60.36 
52-Week High
on 26-Feb-2001
$75.00 
Beta0.76 
Daily Volume (3-month avg)2.92M
Daily Volume (10-day avg)2.46M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-11.9%
52-Week Change
relative to S&P500
+18.2%
Share-Related Items
Market Capitalization$8.97B
Shares Outstanding148.5M
Float142.6M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 28-June-1999
Per-Share Data
Book Value (mrq)$8.49 
Earnings (ttm)$1.85 
Earnings (mrq)$0.47 
Sales (ttm)$6.37 
Cash (mrq)$5.12 
Valuation Ratios
Price/Book (mrq)7.11 
Price/Earnings (ttm)32.56 
Price/Sales (ttm)9.48 
Income Statements
Sales (ttm)$976.8M
EBITDA (ttm)$375.4M
Income available to common (ttm)$284.1M
Profitability
Profit Margin (ttm)29.1%
Operating Margin (ttm)34.3%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)19.58%
Return on Equity (ttm)25.32%
Financial Strength
Current Ratio (mrq)4.37 
Debt/Equity (mrq)0.04 
Total Cash (mrq)$760.0M
Short Interest
As of 8-Aug-2001
Shares Short6.05M
Percent of Float4.2%
Shares Short
(Prior Month)
3.67M
Short Ratio2.16 
Daily Volume2.80M
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.